Ever since Amarin's (NASDAQ:AMRN) new drug Vascepa, which lowers triglyceride levels, was approved in July, the biotech space has been rife with talk of a buyout. It has been previously reported that AstraZeneca (NYSE:AZN) might be considering this purchase, but now an unexpected new company has stepped into the story.
In this video, Motley Fool health care analyst Max Macaluso discusses Teva Pharmaceutical's (NYSE:TEVA) possible interest in Amarin and whether this drugmaker would actually be a better match than AstraZeneca.
David Williamson owns shares of Amarin plc (ADR). Max Macaluso, Ph.D. has no positions in the stocks mentioned above.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.